Pulmatrix, Inc. (Nasdaq: PULM) announced on November 17, 2026, that it has secured SEC effectiveness for its registration statement on Form S-4 and received approval from its stockholders regarding the proposed merger with Eos SENOLYTIX. The company stated that it anticipates closing the transaction by the end of 2026, contingent upon Nasdaq’s approval of the listing of the shares to be issued in the merger and the completion of a reverse stock split approved by stockholders on October 26, 2026.
The merger agreement, entered into on March 26, 2026, involves a wholly owned subsidiary of Pulmatrix merging with and into Eos SENOLYTIX, with Eos surviving as a wholly owned subsidiary of Pulmatrix. In connection with the agreement, Pulmatrix issued and sold $1.0 million in aggregate gross proceeds of newly designated Series B Convertible Preferred Stock to an affiliate of Eos.
Under the terms of the agreement, Eos SENOLYTIX, based in Houston, Texas, will continue its operations as the business of the combined entity. Eos develops MitoXcel geropeptides as therapeutics for obesity, sarcopenia, and other age-related disorders, holding an exclusive license to the MitoXcel platform from its parent company, SENOTHERAPEUTIX, Inc.
In its third quarter 2026 financial results, Pulmatrix reported research and development expenses of less than $0.1 million for the three months ended September 30, 2026. General and administrative expenses increased to $1.2 million for the same period, driven by merger-related activities. The company’s total cash and cash equivalents balance as of September 30, 2026, was $1.4 million, with an additional $0.7 million in restricted cash expected to become unrestricted upon the merger’s completion.
The company’s unaudited financial statements assume the company will continue as a going concern within one year. Pulmatrix noted that its current cash position, based on operational efficiencies, is sufficient to fund operations through the anticipated merger closing.
Pulmatrix’s clinical pipeline includes the iSPERSE technology, which the company believes offers superior drug delivery compared to traditional oral and injectable forms. As of September 30, 2026, the company held approximately 143 granted patents and 47 pending patent applications related to iSPERSE. Key assets include PUR1900, an inhaled itraconazole formulation approved to proceed to Phase 3 in India by partner Cipla, and PUR3100, an inhaled dihydroergotamine for acute migraine that has received FDA approval to proceed with a Phase 2 study.